Socioeconomic Deprivation and the Risk of Sight-Threatening Diabetic Retinopathy (STDR)

Tan, Luyuan; Wang, Jingya; Han, Jieun; Sainsbury, Chris; Denniston, Alastair; Crowe, Francesca; Toulis, Konstantinos; Nirantharakumar, Krishnarajah; Karamat, Muhammad Ali; Yao, Mi

[Link to publication on Research at Birmingham portal](#)

1   **Title:**

2   Socioeconomic deprivation and the risk of sight-threatening diabetic retinopathy (STDR): a

3   population-based cohort study in the UK

4

5   **Authors**

6   Luyuan Tan MSc[1*], Jingya Wang PhD[1*†], Jieun Han MSc[1], Christopher Sainsbury MD[1],

7   Alastair K. Denniston PhD[2,3], Francesca L. Crowe PhD[1], Konstantinos A Toulis PhD[1],

8   Muhammad Ali Karamat MD[4], Mi Yao PhD[5], Krishnarajah Nirantharakumar MD[1†]

9

10   1 Institute of Applied Health Research, University of Birmingham, Birmingham, United

11   Kingdom

12   2 Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, University of

13   Birmingham, Birmingham, United Kingdom

14   3 NIHR Birmingham Biomedical Research Centre, Birmingham, United Kingdom

15   4 Diabetes and Endocrinology Specialist Training Committee, Health Education West

16   Midlands, Birmingham, United Kingdom

17   5 Department of general practice, Peking University First Hospital, Beijing, China

18

19   * Joint First Authors.

20   † Joint Senior Authors

21

22   **Corresponding authors:** Jingya Wang

23   Current address: IOEM Building, University of Birmingham, Edgbaston, Birmingham,

24   B15 2TT, UK

25   Telephone number: +44 (0)759 3945643

26   Email: j.wang.6@bham.ac.uk

27

28   and Krishnarajah Nirantharakumar

29   Current address: IOEM Building, University of Birmingham, Edgbaston, Birmingham,

30   B15 2TT, UK

31   Telephone number: +44 (0)7737 773559

32   Email: k.nirantharan@bham.ac.uk

33

1   **Twitter summary**

2   A UK study reveals an elevated risk of sight-threatening diabetic retinopathy in

3   socioeconomically deprived individuals with diabetes, underscoring health equity issues.

4

5   Word count: 1479

6   Number of tables: 2

7   Number of figures: 1

8

1 **Objective**

2 To evaluate the associations between socioeconomic deprivation and the risk of sight-

3 threatening diabetic retinopathy (STDR) in individuals with type 1 and type 2 diabetes.

4

5 **Research design and methods**

6 Using data derived from 175,628 individuals with diabetes in the Health Improvement Network,

7 we assessed the risk of STDR across Townsend Deprivation Index quantiles using Cox

8 proportional hazard regression models.

9

10 **Results**

11 Compared to the least deprived individuals, those in the most deprived quintile with type 1

12 diabetes had a 2.85 times higher risk of developing STDR (95% CI 1.05-7.73), and those with

13 type 2 diabetes had a 25% higher risk (1.13-1.40).

14

15 **Conclusions**

16 Increasing socioeconomic deprivation is associated with a higher risk of developing STDR in

17 people with diabetes. This underscores persistent health disparities linked to poverty, even

18 within a country offering free universal healthcare. Further research is needed to address health

19 equity concerns in socioeconomically deprived regions.

20

1   **Article highlights**

2   • **Why did we undertake this study?**

3   Deprivation has been associated with various diabetes-related health issues, including

4   morbidity, mortality, and blood glucose levels; however, its specific relationship with

5   sight-threatening diabetic retinopathy (STDR) in people with diabetes remains

6   relatively unclear.

7   • **What is the specific question(s) we wanted to answer?**

8   Whether deprivation played a significant role in the development of STDR in both

9   people with type 1 and type 2 diabetes.

10   • **What did we find?**

11   A higher risk of developing STDR was observed in people with diabetes in more

12   deprived areas.

13   • **What are the implications of our findings?**

14   Within the context of the UK's free universal healthcare system, addressing health

15   equity in deprived areas has the potential to prevent STDR in people with diabetes.

1   **Introduction**

2   Diabetic retinopathy (DR), affecting over one-third of the 537 million adults with diabetes in

3   2021, is a leading cause of preventable blindness (1). Sight-threatening diabetic retinopathy

4   (STDR) is an advanced stage of DR affecting one in ten individuals with diabetes, which

5   presents a significant health burden globally (2). While past studies linked low socioeconomic

6   status with STDR in type 1 diabetes (T1DM), these studies often with small and

7   nonrepresentative populations, lacked dedicated designs and were performed in countries

8   without universal healthcare access (3, 4). In a country with universal healthcare, we aim to

9   rigorously investigate the associations between socioeconomic deprivation and the risk of

10   STDR in individuals with T1DM and type 2 diabetes (T2DM), respectively.

11

12   **Research Design and Methods**

13   Two open cohorts were performed in the Health Improvement Network (THIN), a large

14   primary care-based electronic medical records database generalizable to the UK population for

15   demographics, major condition prevalence, and death rates (5). We included individuals newly

16   diagnosed with T1DM (aged below 40 and with insulin prescription) or those with newly

17   diagnosed T2DM (aged over 16) between 1st January 2005 and 21st February 2020. To ensure

18   only incident diabetes individuals were captured, the study entry began 12 months after

19   registration. Townsend deprivation index quantile was used to measure socioeconomic

20   deprivation, incorporating four components: unemployment, car ownership, homeownership,

21   and household overcrowding (6). As the outcome was incident STDR, individuals with STDR

22   at baseline were excluded. All conditions were identified using Read codes (7).

23

24   All participants were followed up from 15 months after the initial diagnosis date of diabetes (a

25   latency period to minimize reverse causation bias) until the earliest occurrence of first diagnosis

1 of STDR, individuals left practice, practice ceased contributing to the database, death, or study

2 end (21st February 2020).

3

4 The incidence rates (IR) of STDR (per 1,000 person-years) across Townsend quintiles were

5 estimated by Poisson regression. Cox proportional hazard regression models estimated the

6 crude and adjusted hazard ratios (aHR) for STDR, adjusting for key confounding factors: age,

7 sex, ethnicity (grouped and classified based on UK census) (8), weight and height (T1DM

8 cohort), body mass index categories (T2DM cohort), HbA$_{1c}$ categories, smoking status,

9 hypertension, peripheral vascular disease, ischemic heart disease, heart failure, chronic kidney

10 disease, diabetic foot disease, antidiabetic drugs and lipid-lowering drugs. Missing data for

11 ethnicity and smoking status were included in analyses as a missing category. A trend test was

12 conducted using the multivariable-adjusted model. The risk of STDR across age groups and

13 Townsend index missingness status were compared. All statistical tests were two-tailed and a

14 P <0.05 was considered statistically significant. Analyses were conducted using Stata 16.

15

16 **Results**

17 The T1DM cohort and the T2DM cohort comprised 4,406 participants and 171,222 participants,

18 respectively (Figure 1 and Table 1).

19

20 **Type 1 Diabetes (T1DM) Cohort**

21 With a median follow-up of 3.7 years (interquartile range [IQR] 1.6-6.5), 89 of 4,406

22 individuals in the T1DM Cohort developed STDR, reflecting a crude IR of 4.6 per 1,000

23 person-years. Compared to individuals in the lowest two deprivation quintiles, the risk of

24 STDR increased with deprivation levels (trend test: P < 0.001) and reached its highest level in

25 the highest deprivation quintile (aHR 2.85, 95%CI 1.05-7.73) (Table 2).

1

2 **Type 2 Diabetes (T2DM) Cohort**

3 During a median follow-up of 3.8 years (IQR 1.7-6.6), 5, 363 out of 171,222 individuals with

4 T2DM developed STDR, representing a crude IR of 7.1 per 1,000 person-years. The risk of

5 developing STDR was associated with escalating deprivation levels (trend test: $P = 0.001$) and

6 reached its highest level in the highest deprivation quintile (aHR 1.25, 95%CI 1.13-1.40)

7 compared to the lowest deprivation quintile (Table 2).

8

9 The results of age subgroup analyses were consistent with the main findings (Table 2). Unlike

10 the unchanged STDR risk in the T1DM cohort, individuals without Townsend index exhibited

11 a slightly higher STDR risk (aHR 1.20, 95%CI 1.12-1.28) compared to those with Townsend

12 index in the T2DM cohort.

13

14 **Conclusions**

15 We found that the risk of developing STDR increases with elevated levels of deprivation in

16 individuals with T1DM and those with T2DM. Compared with the least deprived group,

17 individuals with T1DM and T2DM in the most deprived group had nearly three times and 25%

18 higher risk of STDR, respectively. In a country with free universal healthcare, the observed

19 difference in the risk of STDR among different socioeconomic deprivation levels could be

20 largely attributed to underlying factors beyond healthcare access. Our findings highlight the

21 importance of implementing comprehensive health equity strategies that engage diverse

22 stakeholders and prioritize proactive management and care in socioeconomically

23 disadvantaged areas.

24

1 Similar to our results, a recent US study using data derived from 1,116,361 adults with diabetes

2 reported that the risk of hypoglycemic and hyperglycemic crises increases with the elevated

3 level of socioeconomic deprivation (9). The results of a Scottish primary care-based study were

4 partly similar to our findings. After adjusting for age and gender, a higher prevalence of DR in

5 individuals with T1DM (n = 1861) was observed only in the most deprived quintile (aHR 2.40,

6 95% CI 1.36-4.27), compared to the least deprived quintile. No association was observed

7 between deprivation and the prevalence of DR in individuals with T2DM (n = 18,197) (10).

8 Conversely, another large UK primary care-based study with 7.7 million participants reported

9 an association of deprivation with the incidence of DR/severe retinopathy in individuals with

10 T2DM (no trend was observed), but not in individuals with T1DM (11). While these studies

11 provide valuable insights, their capacity to furnish precise estimates is hindered by flaws within

12 their designs (e.g. failure to exclude individuals with the outcome of interests at baseline and

13 to adjust for essential confounders [e.g. smoking, HbA_{1c} levels, and comorbidities]) (10, 11).

14

15 The evident association of deprivation with the risk of STDR in individuals living with diabetes

16 observed in a country with a universal healthcare system are possibly attributed to underlying

17 factors beyond healthcare access. Firstly, the built environment plays a pivotal role, where

18 inadequate housing conditions, deficient community infrastructure, and limited access to green

19 spaces intertwine, impacting overall well-being and health conditions (12). Secondly, restricted

20 educational opportunities and lower health literacy in these areas may lead to limited

21 engagement in health awareness programs and social support networks, impacting preventive

22 health behaviors, such as diabetes self-management and actively attending eye screening and

23 treatment programs (13, 14). Thirdly, the racial composition and its related language barriers,

24 even with free interpreter service and proactive investigations on race inequality, may still pose

25 significant hurdles, impeding effective communication with healthcare providers and access to

1 healthcare services and essential health information (15, 16). Lastly, fragmented social

2 structures and weakened community connections exacerbate the impact of the aforementioned

3 factors, limiting resource access, hindering community engagement, and elevating stress levels

4 within deprived areas, thus perpetuating health disparities (17-19). Addressing these

5 multifaceted issues requires comprehensive interventions spanning socioeconomic,

6 environmental, and educational domains to improve the overall well-being of deprived

7 communities.

8

9 Given that the National Health Service (NHS) offers universal free healthcare services and

10 medications to all individuals in the UK, the observed variations in the risk of STDR among

11 different socioeconomic deprivation groups suggested that health equity becomes crucial in

12 socioeconomically disadvantaged regions. Individuals with lower incomes were more likely to

13 have greater healthcare requirements (20), suggesting that prioritized healthcare services,

14 rather than equitable provision, should be addressed in deprived communities. When providing

15 healthcare services, socioeconomic disadvantage and health requirements should be considered

16 as critical determinants, since increased NHS resources invested in the most impoverished

17 areas might generate a bigger absolute increase in health outcomes compared to the wealthier

18 regions (21). Given that individuals with high levels of deprivation are less likely to utilize

19 planned and preventative healthcare services (22), it is essential to implement targeted

20 healthcare interventions, such as promoting participation in DR screening programs and

21 providing educational activities to enhance self-glucose control skills.

22

23 The large sample size, longitudinal population-based study design, and long follow-up period

24 have ensured that the data in this study are nationally generalizable. The adjustment of

25 important potential confounders has improved the power of the associations between

socioeconomic deprivation and STDR. However, a limitation arises from the approximately 16% missing data in Townsend deprivation indices. To address this, we conducted a sensitivity analysis comparing the risk of STDR between individuals with and without Townsend index to offer a comprehensive picture to readers. While ethnicity has been fully controlled in our analyses, if we hold a sufficient number of participants from minority groups, performing subgroup analyses in different ethnic groups would surely strengthen our conclusion. Lastly, our study had constraints in examining associations between individual components of the Townsend index and STDR due to data unavailability. Nonetheless, the Townsend index, a widely recognized composite measure, affords a more holistic assessment of deprivation than its individual elements.

In conclusion, we found socioeconomic deprivation was associated with the increased risk of STDR in people with T1DM and T2DM. This study highlights the importance of addressing health equity concerns and its relevance to the prevention of STDR.

Reference:

1. Federation ID. Diabetes around the world in 2021: International Diabetes Federation; 2022 [Available from: https://diabetesatlas.org/#:~:text=1%20in%208%20adults%20(206,caused%20by%20diabetes%20in%202021.

2. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care. 2012;35(3):556-64.

3. Bihan H, Laurent S, Sass C, Nguyen G, Huot C, Moulin JJ, et al. Association among individual deprivation, glycemic control, and diabetes complications: the EPICES score. Diabetes care. 2005;28(11):2680-5.

4. Alvarez-Ramos P, Jimenez-Carmona S, Alemany-Marquez P, Cordoba-Doña JA, Aguilar-Diosdado M. Socioeconomic deprivation and development of diabetic retinopathy in patients with type 1 diabetes mellitus. BMJ Open Diabetes Research and Care. 2020;8(2):e001387.

5. Blak B, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Journal of Innovation in Health Informatics. 2011;19(4):251-5.

6. Townsend P. Deprivation. Journal of Social Policy. 1987;16(2):125-46.

7. Luyuan Tan JH, Christopher Sainsbury, Alastair K. Denniston, Francesca L. Crowe, Konstantinos A Toulis, Muhammad Ali Karamat, Mi Yao, Krishnarajah Nirantharakumar, Jingya Wang. Appendix 1-3 and Appendix Table 1-2 Github: Github; 2023 [Available from: https://github.com/Freyaaay/Deprivation/blob/85546e1c6f75aa3970421f439327515bccf2dcb3/Appendix.docx.

8. GOV.UK. List of ethnic groups: GOV.UK; 2021 [Available from:

1 https://www.ethnicity-facts-figures.service.gov.uk/style-guide/ethnic-groups.

2 9.   Kurani SS, Heien HC, Sangaralingham LR, Inselman JW, Shah ND, Golden SH, et al.

3 Association of area-level socioeconomic deprivation with hypoglycemic and hyperglycemic

4 crises in US adults with diabetes. JAMA Network Open. 2022;5(1):e2143597-e.

5 10.   Low L, Law JP, Hodson J, McAlpine R, O'Colmain U, MacEwen C. Impact of

6 socioeconomic deprivation on the development of diabetic retinopathy: a population-based,

7 cross-sectional and longitudinal study over 12 years. BMJ open. 2015;5(4).

8 11.   Mathur R, Bhaskaran K, Edwards E, Lee H, Chaturvedi N, Smeeth L, et al. Population

9 trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study

10 in the Clinical Practice Research Datalink 2004–2014. BMJ open. 2017;7(2):e014444.

11 12.   Gibson M, Petticrew M, Bambra C, Sowden AJ, Wright KE, Whitehead M. Housing

12 and health inequalities: a synthesis of systematic reviews of interventions aimed at different

13 pathways linking housing and health. Health & place. 2011;17(1):175-84.

14 13.   Tan ST, Quek RYC, Haldane V, Koh JJK, Han EKL, Ong SE, et al. The social

15 determinants of chronic disease management: perspectives of elderly patients with

16 hypertension from low socio-economic background in Singapore. International journal for

17 equity in health. 2019;18(1):1-14.

18 14.   Bachmann M, Eachus J, Hopper C, Davey Smith G, Propper C, Pearson N, et al. Socio-

19 economic inequalities in diabetes complications, control, attitudes and health service use: a

20 cross-sectional study. Diabetic Medicine. 2003;20(11):921-9.

21 15.   Zheng Y, Lamoureux EL, Chiang P-CP, Anuar AR, Ding J, Wang JJ, et al. Language

22 barrier and its relationship to diabetes and diabetic retinopathy. BMC public health. 2012;12:1-

23 9.

24 16.   Cheung N, Chee ML, Klein R, Klein BE, Shea S, Cotch MF, et al. Incidence and

25 progression of diabetic retinopathy in a multi-ethnic US cohort: the Multi-Ethnic Study of

1   Atherosclerosis. British Journal of Ophthalmology. 2022;106(9):1264-8.

2   17.   Whitley E, Gunnell D, Dorling D, Smith GD. Ecological study of social fragmentation,

3   poverty, and suicide. bmj. 1999;319(7216):1034-7.

4   18.   Allardyce J, Gilmour H, Atkinson J, Rapson T, Bishop J, McCreadie R. Social

5   fragmentation, deprivation and urbanicity: relation to first-admission rates for psychoses. The

6   British Journal of Psychiatry. 2005;187(5):401-6.

7   19.   Grigoroglou C, Munford L, Webb RT, Kapur N, Ashcroft DM, Kontopantelis E. Spatial

8   distribution and temporal trends in social fragmentation in England, 2001− 2011: a national

9   study. BMJ open. 2019;9(1):e025881.

10   20.   Marmot M. Fair society, healthy lives. Fair society, healthy lives. 2013:1-74.

11   21.   Barr B, Bambra C, Whitehead M. The impact of NHS resource allocation policy on

12   health inequalities in England 2001-11: longitudinal ecological study. Bmj. 2014;348.

13   22.   Goddard M, Smith P. Equity of access to health care services:: Theory and evidence

14   from the UK. Social science & medicine. 2001;53(9):1149-62.

15

Table 1. Baseline characteristics of individuals with type 1 and type 2 diabetes across Townsend Deprivation Index quintiles

Type 1 diabetes	Townsend Deprivation Index				
	1 (*n* = 811) (lowest deprivation)	**2 (*n* = 752)**	**3 (*n* = 778)**	**4 (*n* = 687)**	**5 (*n* = 573) (highest deprivation)**
Age (years), mean $\pm$ SD	15.3 $\pm$ 8.5	17.1 $\pm$ 9.6	17.5 $\pm$ 9.5	18.0 $\pm$ 10.0	18.2 $\pm$ 10.5
Male, *n* (%)	479 (59.1)	431 (57.3)	455 (58.5)	403 (58.7)	348 (60.7)
Ethnicity, *n* (%)					
White	347 (42.8)	323 (43.0)	361 (46.4)	321 (46.7)	267 (46.6)
Mixed or Multiples	1 (0.1)	2 (0.3)	1 (0.1)	3 (0.4)	6 (1.1)
Other ethnic groups	4 (0.5)	1 (0.1)	2 (0.3)	5 (0.7)	3 (0.5)
Black, Black British, Black Welsh, Caribbean or African	0 (0.0)	5 (0.7)	4 (0.5)	4 (0.6)	9 (1.6)
Asian, Asian British, Asian Welsh	7 (0.9)	6 (0.8)	11 (1.4)	6 (0.9)	7 (1.2)
Missing	452 (55.7)	415 (55.2)	399 (51.3)	348 (50.7)	281 (49.0)
Smoking Status, *n* (%)					
Smoker	43 (5.3)	70 (9.3)	86 (11.1)	93 (13.5)	125 (21.8)
Ex-smoker	34 (4.2)	40 (5.3)	59 (7.6)	46 (6.7)	31 (5.4)
Non-smoker	301 (37.1)	280 (37.2)	295 (37.9)	262 (38.1)	192 (33.5)
Missing	433 (53.4)	362 (48.1)	338 (43.4)	286 (41.6)	225 (39.3)
HbA$_{1c}$ level, *n* (%)					
<6.5%	113 (13.9)	118 (15.7)	100 (12.9)	102 (14.9)	73 (12.7)
6.5-7.5%	179 (22.1)	191 (25.4)	168 (21.6)	131 (19.1)	106 (18.5)
7.5-8.5%	177 (21.8)	152 (20.2)	160 (20.6)	143 (20.8)	120 (20.9)
$\geq$8.5%	179 (22.1)	172 (22.9)	217 (27.9)	187 (27.2)	176 (30.7)
Missing	163 (20.1)	119 (15.8)	133 (17.1)	124 (18.1)	98 (17.1)
Hypertension, *n* (%)	1 (0.1)	7 (0.9)	4 (0.5)	10 (1.5)	10 (1.8)
Chronic kidney disease, *n* (%)	5 (0.6)	9 (1.2)	7 (0.9)	10 (1.5)	12 (2.1)
Diabetic Foot Disease, *n* (%)	10 (1.2)	16 (2.1)	5 (0.6)	11 (1.6)	7 (1.2)
Metformin, *n* (%)	23 (2.8)	28 (3.7)	33 (4.2)	30 (4.4)	39 (6.8)

Lipid-lowering drugs, *n (%)*	14 (1.7)	14 (1.9)	19 (2.4)	21 (3.1)	21 (3.7)

Type 2 diabetes	**Townsend Deprivation Index**				
	1 (*n* = 30,909) (lowest deprivation)	**2 (*n* = 29,765)**	**3 (*n* = 31,049)**	**4 (*n* = 29,087)**	**5 (*n* = 22,181) (highest deprivation)**
Age (years), mean $\pm$ SD	64.3 $\pm$ 12.3	64.4 $\pm$ 12.6	62.8 $\pm$ 13.1	61.9 $\pm$ 13.6	60.3 $\pm$ 13.6
Male, *n (%)*	18,314 (59.3)	17,044 (57.3)	17,326 (55.8)	15,647 (53.8)	11,679 (56.7)
Ethnicity, *n (%)*					
White	13,102 (42.4)	13,492 (45.3)	14,183 (45.7)	13,510 (46.5)	11,117 (50.1)
Mixed or Multiples	140 (0.5)	119 (0.4)	189 (0.6)	200 (0.7)	227 (1.0)
Other ethnic groups	45 (0.2)	49 (0.2)	61 (0.2)	85 (0.3)	78 (0.4)
Black, Black British, Black Welsh, Caribbean or African	157 (0.5)	167 (0.6)	352 (1.1)	484 (1.7)	681 (3.1)
Asian, Asian British, Asian Welsh	572 (1.9)	563 (1.9)	984 (3.2)	1,227 (4.2)	1,017 (4.6)
Missing	16,893 (54.7)	15,375 (51.7)	15,280 (49.2)	13,581 (46.7)	9,061 (40.9)
Smoking Status, *n (%)*					
Smoker	3,056 (9.9)	3,640 (12.2)	5,016 (16.2)	5,850 (20.1)	5,740 (25.9)
Ex-smoker	11,324 (36.6)	11,139 (37.4)	11,545 (37.2)	10,675 (36.7)	7,546 (34.0)
Non-smoker	16,474 (53.3)	14,954 (50.2)	14,443 (46.5)	12,533 (43.1)	8,865 (40.0)
Missing	55 (0.2)	32 (0.1)	45 (0.1)	29 (0.1)	30 (0.1)
BMI (kg/m^2), mean $\pm$ SD	30.6 $\pm$ 6.0	31.2 $\pm$ 6.3	31.8 $\pm$ 6.7	32.3 $\pm$ 6.9	32.6 $\pm$ 7.2
HbA$_{1c}$ level, *n (%)*					

≤6.5%	13,711 (44.4)	12,714 (42.7)	12,822 (41.3)	11,516 (39.6)	8,485 (38.3)
6.5-7.5%	11,975 (38.7)	11,637 (39.1)	11,918 (38.4)	11,233 (38.6)	8,531 (38.5)
7.5-8.5%	2,719 (8.8)	2,885 (9.7)	3,204 (10.3)	3,027 (10.4)	2,396 (10.8)
≥8.5%	1,844 (6.0)	1,989 (6.7)	2,446 (7.9)	2,624 (9.0)	2,269 (10.2)
Missing	660 (2.1)	540 (1.8)	659 (2.1)	687 (2.4)	500 (2.3)
Hypertension, *n (%)*	17,162(55.5)	16,668 (56.0)	17,060 (55.0)	15,535 (53.4)	11,546 (52.1)
Peripheral vascular disease, *n (%)*	730 (2.4)	832 (2.8)	947 (3.1)	1,025 (3.5)	928 (4.2)
Stroke, *n (%)*	2,088 (6.8)	2,227 (7.5)	2,233 (7.2)	2,137 (7.4)	1,714 (7.7)
Ischemic heart disease, *n (%)*	4,996 (16.2)	5,074 (17.1)	5,280 (17.0)	5,226 (18.0)	4,043 (18.2)
Heart Failure, *n (%)*	923 (3.0)	1,013 (3.4)	1,101 (3.6)	1,168 (4.0)	924 (4.2)
Chronic kidney diseases, *n (%)*	5,428 (17.6)	5,396 (18.1)	5,238 (16.9)	4,963 (17.1)	3,404 (15.4)
Diabetic Foot Disease, *n (%)*	4,226 (13.7)	4,309 (14.5)	46,97 (15.1)	4,462 (15.3)	3,635 (16.4)
Metformin, *n (%)*	15,560 (50.3)	14,995 (50.4)	16,831 (54.2)	16,467 (56.6)	13,125 (59.2)
Insulin, *n (%)*	1,756 (5.7)	1,775 (6.0)	2,154 (6.9)	2,213 (7.6)	1,873 (8.4)
Other glucose-lowering medications, *n (%)*	4,370 (15.9)	4,380 (16.0)	5,012 (18.3)	4,997 (18.2)	4,141 (15.1)
Lipid-lowering drugs, *n (%)*	22,600 (73.1)	21,720 (73.0)	22,716 (73.2)	21,220 (73.0)	16,347 (73.7)

SD, standard deviation; HbA$_{1c}$, hemoglobin A1c.

Table 2. The risk of developing sight-threatening diabetic retinopathy (STDR) across Townsend deprivation index quintiles in individuals with type 1 and type 2 diabetes

Type 1 Diabetes	Townsend Deprivation Index				
	1 (lowest deprivation)	2	3	4	5 (highest deprivation)
N	811	752	778	687	573
STDR, *n (%)*	6 (0.7)	9 (1.2)	17 (2.2)	25 (3.6)	16 (2.8)
Person-years	3,582.1	3,377.7	3,454.1	2,913.9	2,568.2
Incidence rate (per 1,000 person-years)	1.7	2.7	4.9	8.6	6.2
Crude HR (95% CI)	Ref	1.69 (0.59-4.89)	2.67 (1.01-7.03)	5.08 (2.05-12.60)	4.15 (1.61-10.72)
Adjusted HR (95% CI) [*]	Ref	0.98 (0.32-3.08)	1.42 (0.50-4.03)	2.05 (0.76-5.55)	2.85 (1.05-7.73)
			Trend test: P <0.001		
By age					
<18 years (Adjusted HR, 95% CI)	Ref	0.38 (0.04-3.80)	1.03 (0.20-5.27)	2.56 (0.60-11.08)	2.88 (0.65-12.80)
≥18 years (Adjusted HR, 95% CI)	Ref	1.10 (0.29-5.32)	1.47 (0.36-6.01)	1.64 (0.43-6.35)	2.42 (0.61-9.59)

Type 2 Diabetes	Townsend Deprivation Index				
	1 (lowest deprivation)	2	3	4	5 (highest deprivation)
N	30,909	29,765	31,049	29,087	22,181
STDR, *n (%)*	881 (2.9)	858 (2.9)	942 (3.0)	930 (3.2)	701 (3.2)
Person-years	137,627.6	130,988.2	136,477.3	125,716.4	95,856.6
Incidence rate (per 1,000 person-years)	6.4	6.6	6.9	7.4	7.3
Crude HR (95% CI)	Ref	1.04 (0.94-1.15)	1.06 (0.96-1.17)	1.13 (1.02-1.24)	1.17 (1.05-1.30)
Adjusted HR (95% CI) [†]	Ref	1.06 (0.95-1.17)	1.08 (0.98-1.20)	1.18 (1.07-1.31)	1.25 (1.13-1.40)
			Trend test: P = 0.001		

By age

<65 years (Adjusted HR, 95% CI)	Ref	1.02 (0.89-1.17)	1.12 (0.98-1.29)	1.20 (1.05-1.38)	1.21 (1.04-1.42)
≥65 years (Adjusted HR, 95% CI)	Ref	1.08 (0.93- 1.27)	1.01 (0.87-1.18)	1.11 (0.96-1.30)	1.24 (1.07-1.45)

STDR, sight-threatening diabetic retinopathy; HR, hazard ratio; Ref, reference group; CI, confidence interval.

*Adjusted for age, sex, ethnicity, weight, height, HbA_{1c}, smoking status, hypertension, chronic kidney disease (stage 3 to 5), diabetic foot disease, glucose-lowering medicine, and lipid-lowering medicine.

[†]Adjusted for age, sex, ethnicity, body mass index, HbA_{1c}, smoking status, hypertension, chronic kidney disease (stage 3 to 5), diabetic foot disease, glucose-lowering medicine, lipid-lowering medicine, peripheral vascular disease, ischemic heart disease stroke, and heart failure.